Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2025 Feb 12

PMID 39936036

Authors

Yuqing Cui

Xin Liu

Sizhou Feng

Affiliations

Soon will be listed here.

Abstract

Purpose: Since the publication of the 2011 Infectious Diseases Society of America (IDSA) guidelines for empirical treatment of febrile neutropenia (FN), there have been significant shifts in pathogen profiles and emerging challenges in treatment. These include increased prevalence of multidrug-resistant (MDR) bacteria and changes in the distribution of Gram-negative or Gram-positive bacteria (GPB). The study aims to update and optimize empirical treatment strategies for hematological malignancy (HM) patients, a population particularly vulnerable to these evolving threats.

Methods: A literature review was conducted on studies published between January 2010 and December 2023 regarding empirical treatment of FN in HM patients, focusing on pathogen characteristics, treatment regimens, and duration of therapy.

Results: Approximately one-third of HM patients with FN experience fever of unknown origin (FUO), while 40-50% have clinically documented infections (CDI), and 10-30% present with microbiologically documented infections (MDI), with a predominance of Gram-negative bacteria (GNB). Factors such as prolonged neutropenia, prior broad-spectrum antibiotic use, and previous infections with drug-resistant bacteria are associated with MDR infections. Cefepime, piperacillin/tazobactam (PTZ), and carbapenem are viable empirical treatments for high-risk HM patients, though cefepime monotherapy's advantage remains uncertain. In cases of pneumonia, shock, or suspected carbapenem-resistant infections, combination therapy, tigecycline, and newer antibiotics like ceftazidime/avibactam (CAZ/AVI) are often used. Empirical broad-spectrum antibiotics can be safely discontinued in FUO patients after 48 hours of clinical stability and apyrexia.

Conclusion: Proper selection of empirical antibiotics and determining optimal treatment duration are essential for reducing antibiotic resistance and improving outcomes in HM patients with FN. These findings underscore the need for updated clinical guidelines that address evolving pathogen profiles and the growing challenge of MDR infections.

References

Prosty C, Katergi K, Nguyen A, Luo O, Sorin M, Cherniak V . Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs. Blood Adv. 2023; 8(4):857-866. PMC: 10875332. DOI: 10.1182/bloodadvances.2023011964. View

Averbuch D, Orasch C, Cordonnier C, Livermore D, Mikulska M, Viscoli C . European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013; 98(12):1826-35. PMC: 3856957. DOI: 10.3324/haematol.2013.091025. View

Rearigh L, Stohs E, Freifeld A, Zimmer A . De-escalation of empiric broad spectrum antibiotics in hematopoietic stem cell transplant recipients with febrile neutropenia. Ann Hematol. 2020; 99(8):1917-1924. PMC: 7340662. DOI: 10.1007/s00277-020-04132-0. View

Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L . Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013; (6):CD003038. PMC: 6457814. DOI: 10.1002/14651858.CD003038.pub2. View

Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A . Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017; 65(11):1884-1896. DOI: 10.1093/cid/cix690. View

Liu C, Lai Y, Huang L, Yang Y, Chen T, Hsiao L . Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2010; 46(9):1231-9. DOI: 10.1038/bmt.2010.286. View

Viasus D, Puerta-Alcalde P, Cardozo C, Suarez-Lledo M, Rodriguez-Nunez O, Morata L . Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin Microbiol Infect. 2019; 26(3):345-350. DOI: 10.1016/j.cmi.2019.07.002. View

Yan C, Xu T, Zheng X, Sun J, Duan X, Gu J . [Epidemiology of febrile neutropenia in patients with hematological disease-a prospective multicentre survey in China]. Zhonghua Xue Ye Xue Za Zhi. 2016; 37(3):177-82. PMC: 7342950. DOI: 10.3760/cma.j.issn.0253-2727.2016.03.001. View

Chumbita M, Puerta-Alcalde P, Gudiol C, Garcia-Pouton N, Laporte-Amargos J, Ladino A . Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock. Antimicrob Agents Chemother. 2021; 66(2):e0174421. PMC: 8846468. DOI: 10.1128/AAC.01744-21. View

10.

Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T . Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017; 23(10):723-729. DOI: 10.1016/j.cmi.2017.03.024. View

11.

Kolonen A, Sinisalo M, Huttunen R, Syrjanen J, Aittoniemi J, Huhtala H . Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study. Infect Dis (Lond). 2017; 49(11-12):799-808. DOI: 10.1080/23744235.2017.1347814. View

12.

Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L . Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014; (1):CD003914. DOI: 10.1002/14651858.CD003914.pub3. View

13.

Aguilar-Guisado M, Espigado I, Martin-Pena A, Gudiol C, Royo-Cebrecos C, Falantes J . Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017; 4(12):e573-e583. DOI: 10.1016/S2352-3026(17)30211-9. View

14.

Schauwvlieghe A, Dunbar A, Storme E, Vlak A, Aerts R, Maertens J . Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study. EClinicalMedicine. 2021; 35:100855. PMC: 8099620. DOI: 10.1016/j.eclinm.2021.100855. View

15.

Sereeaphinan C, Kanchanasuwan S, Julamanee J . Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study. IJID Reg. 2022; 1:5-11. PMC: 9216401. DOI: 10.1016/j.ijregi.2021.09.002. View

16.

Snyder M, Pasikhova Y, Baluch A . Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective Review. Open Forum Infect Dis. 2017; 4(4):ofx226. PMC: 5726466. DOI: 10.1093/ofid/ofx226. View

17.

Rosa R, Goldani L, Dos Santos R . Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. Am J Infect Control. 2013; 42(1):74-6. DOI: 10.1016/j.ajic.2013.06.025. View

18.

Zhao Y, Lin Q, Zhang T, Zhen S, Wang J, Jiang E . Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: Clinical outcomes and prediction model of multidrug-resistant infections. J Infect. 2022; 86(1):66-117. DOI: 10.1016/j.jinf.2022.08.037. View

19.

Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L . Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017; 65(11):1819-1828. DOI: 10.1093/cid/cix646. View

20.

Kim P, Wu Y, Cooper C, Rochester G, Valappil T, Wang Y . Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis. 2010; 51(4):381-9. DOI: 10.1086/655131. View